Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Myeloproliferative Disorders 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine 27Azacitidine 27venetoclax 24Cyclophosphamide 22Specimen Handling 21fludarabine phosphate 17Biopsy 16Whole-Body Irradiation 15Mycophenolic Acid 15Busulfan 15Melphalan 14Cytarabine 14Tacrolimus 13Granulocyte Colony-Stimulating Factor 12Decitabine 11Stem Cell Transplantation 10Injections 10Cyclosporine 10decitabine and cedazuridine drug combination 9Sirolimus 9Filgrastim 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7X-Rays 6Idarubicin 6ruxolitinib 5Cyclosporins 5Cladribine 5Methotrexate 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Liposomes × 90 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡